V
Victoria Zazulina
Researcher at Boehringer Ingelheim
Publications - 14
Citations - 8657
Victoria Zazulina is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Afatinib & Lung cancer. The author has an hindex of 12, co-authored 13 publications receiving 7410 citations. Previous affiliations of Victoria Zazulina include AstraZeneca.
Papers
More filters
Journal ArticleDOI
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist,James Chih-Hsin Yang,Nobuyuki Yamamoto,Kenneth J. O'Byrne,Vera Hirsh,Tony Mok,Sarayut Lucien Geater,Sergey Orlov,Chun-Ming Tsai,Michael Boyer,Wu Chou Su,Jaafar Bennouna,Terufumi Kato,Vera Gorbunova,Ki Hyeong Lee,Riyaz Shah,Dan Massey,Victoria Zazulina,Mehdi Shahidi,Martin Schuler +19 more
TL;DR: The LUX-Lung 3 study as mentioned in this paper investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epIDERmal growth factors receptor 2 (HER2/ERbB2), and ErbbB4 and has wide-spectrum preclinical activity against EGFR mutations.
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
Lecia V. Sequist,James Chih-Hsin Yang,Nobuyuki Yamamoto,Kenneth J. O'Byrne,Vera Hirsh,Tony Mok,Sarayut Lucien Geater,Sergey Orlov,Chun-Ming Tsai,Michael Boyer,Wu Chou Su,Jaafar Bennouna,Terufumi Kato,Vera Gorbunova,Ki Hyeong Lee,Riyaz Shah,Dan Massey,Victoria Zazulina,Mehdi Shahidi,Martin Schuler +19 more
TL;DR: Afatinib is associated with prolongation of PFS when compared with standard doublet chemotherapy in patients with advanced lung adenocarcinoma and EGFR mutations.
Journal ArticleDOI
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih-Hsin Yang,Yi-Long Wu,Martin Schuler,Martin Sebastian,Sanjay Popat,Nobuyuki Yamamoto,Caicun Zhou,Cheng Ping Hu,Kenneth J. O'Byrne,Jifeng Feng,Shun Lu,Yunchao Huang,Sarayut Lucien Geater,Kye Young Lee,Chun-Ming Tsai,Vera Gorbunova,Vera Hirsh,Jaafar Bennouna,S. M. Orlov,Tony Mok,Michael Boyer,Wu Chou Su,Ki Hyeong Lee,Terufumi Kato,Dan Massey,Mehdi Shahidi,Victoria Zazulina,Lecia V. Sequist +27 more
TL;DR: In this article, the effect of Afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials was evaluated.
Journal ArticleDOI
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
James Chih-Hsin Yang,Lecia V. Sequist,Sarayut Lucien Geater,Chun-Ming Tsai,Tony Mok,Martin Schuler,Nobuyuki Yamamoto,Chong-Jen Yu,Sai-Hong Ignatius Ou,Caicun Zhou,Dan Massey,Victoria Zazulina,Yi-Long Wu +12 more
TL;DR: Afatinib was active in non-small-cell lung cancer tumours that harboured certain types of uncommon EGFR mutations, especially Gly719Xaa, Leu861Gln, and Ser768Ile, but less active in other mutations types.
Journal ArticleDOI
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
Pasi A. Jänne,Alice T. Shaw,José Rodrigues Pereira,Gaelle Jeannin,Johan Vansteenkiste,Carlos H. Barrios,Fabio Franke,Lynda Grinsted,Victoria Zazulina,Paul D. Smith,Ian C. Smith,Lucio Crinò +11 more
TL;DR: A prospective, randomised, phase 2 trial to assess selumetinib plus docetaxel in previously treated patients with advanced KRAS-mutant NSCLC found promising efficacy, albeit with a higher number of adverse events.